Unicycive Therapeutics Income Statement (2020-2026) | UNCY

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.95M0.68M
Operating items
Research & Development (Quarter)
0.27M3.78M-4.00M1.93M0.08M4.80M12.13M3.03M2.27M3.37M4.23M6.81M4.87M3.04M5.29M2.17M1.75M2.96M2.25M1.61M
Selling, General & Administrative (Quarter)
0.02M0.94M0.13M1.60M0.06M1.70M1.49M1.85M2.06M2.57M2.08M2.39M2.53M3.21M3.97M5.82M5.21M4.38M4.97M6.83M
Other Operating Expenses (Quarter)
0.48M6.62M3.49M-0.00M-8.29M-10.37M0.48M1.60M
Operating Expenses (Quarter)
0.78M4.71M2.75M3.54M3.64M6.50M5.33M4.88M4.32M5.94M6.31M9.20M7.40M6.25M9.26M7.99M6.96M7.34M7.22M8.44M
Operating Income (Quarter)
-0.78M-4.71M-2.75M-3.54M-3.64M-5.55M-5.33M-4.20M-4.32M-5.94M-6.31M-9.20M-7.40M-6.25M-9.26M-7.99M-6.96M-7.34M-7.22M-8.44M
EBIT (Quarter)
-0.78M-4.71M-2.75M-3.54M-3.64M-5.55M-5.33M-4.20M-4.32M-5.94M-6.31M-9.20M-7.40M-6.25M-9.26M-7.99M-6.96M-7.34M-7.22M-8.44M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.23M0.23M0.14M0.07M0.46M0.42M0.31M0.23M0.15M0.28M0.35M0.39M
Other Non Operating Income (Quarter)
-10.37M-11.76M
Non Operating Income (Quarter)
-0.32M-0.49M-0.00M-0.00M-10.37M0.48M1.60M-1.49M-11.76M17.26M2.15M-12.26M8.56M0.52M1.33M-7.44M-4.39M
Net income details
EBT (Quarter)
-1.10M-4.77M-2.75M-3.54M-3.64M-5.56M-5.33M-4.20M-4.12M-5.73M-6.19M-9.15M-6.96M-5.85M-8.97M-7.78M-6.82M-7.08M-6.90M-8.04M
Profit After Tax (Quarter)
-1.10M-5.20M-2.75M-3.54M-3.64M-5.56M-5.33M-14.57M-3.84M-4.33M-7.80M-20.96M9.86M-4.10M-21.52M0.57M-6.45M-6.01M-14.67M-12.82M
Income from Continuing Operations (Quarter)
-1.10M-4.77M-2.75M-3.54M-3.64M-5.56M-5.33M-4.20M-4.12M-5.73M-6.19M-9.15M-6.96M-5.85M-8.97M-7.78M-6.82M-7.08M-6.90M-8.04M
Consolidated Net Income (Quarter)
-1.10M-4.77M-2.75M-3.54M-3.64M-5.56M-5.33M-4.20M-4.12M-5.73M-6.19M-9.15M-6.96M-5.85M-8.97M-7.78M-6.82M-7.08M-6.90M-8.04M
Income towards Parent Company (Quarter)
-1.10M-4.77M-2.75M-3.54M-3.64M-5.56M-5.33M-4.20M-4.12M-5.73M-6.19M-9.15M-6.96M-5.85M-8.97M-7.78M-6.82M-7.08M-6.90M-8.04M
Preferred Dividend Payments (Quarter)
0.19M0.60M0.07M0.21M0.89M
Net Income towards Common Stockholders (Quarter)
-1.10M-5.20M-2.75M-3.54M-3.64M-5.56M-5.33M-14.77M-4.44M-4.41M-7.80M-21.17M3.04M-4.10M-21.52M0.51M-6.45M-6.01M-14.67M-12.82M
Additional items
EPS (Basic) (Quarter)
-0.13-0.37-0.17-0.24-0.24-0.37-0.35-0.97-0.29-0.13-0.16-0.610.80-0.46-2.640.04-0.52-0.33-0.82-0.54
EPS (Weighted Average and Diluted) (Quarter)
-0.13-0.49-0.24-0.24-0.24-0.37-0.35-0.97-0.29-0.13-0.16-0.61-1.50-0.46-2.64-0.50-0.52-0.33-0.82-0.54
Shares Outstanding (Weighted Average) (Quarter)
8.77M10.54M11.68M15.00M15.03M15.05M15.06M15.23M15.23M21.10M24.54M34.91M3.79M5.41M6.70M11.68M11.99M18.07M15.89M23.91M
Shares Outstanding (Diluted Average) (Quarter)
8.68M10.54M11.68M15.00M15.02M15.06M15.06M15.23M15.23M32.63M24.54M34.91M9.41M8.89M6.70M12.38M11.99M18.07M15.89M23.91M
EBITDA (Quarter)
-0.78M-4.71M-2.75M-3.54M-3.64M-5.55M-5.33M-4.20M-4.32M-5.94M-6.31M-9.20M-7.40M-6.25M-9.26M0.57M-6.96M-7.34M-7.22M-12.82M
Interest Expenses (Quarter)
0.32M0.06M0.00M0.00M0.01M0.03M0.02M0.02M0.02M0.02M0.01M0.02M0.01M0.01M0.01M0.03M